

Reference number
1684-H

SPECIALTY QUANTITY LIMIT PROGRAM

TAFINLAR (dabrafenib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of melanoma fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Tafinlar 50 mg capsule	120 per 30 days	Standard: 150 mg twice daily First dose reduction: 100 mg twice daily Second dose reduction: 75 mg twice daily Third dose reduction: 50 mg twice daily
Tafinlar 75 mg capsule	120 per 30 days	

III. REFERENCES

1. Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corporation; June 2016.